Stéphane Bancel (Photo by Steven Ferdman/Getty Images)
February 15, 2022 01:36 PM ESTUpdated 05:08 PM
Bioregnum
Pharma

Mod­er­na’s once high-fly­ing stock buck­les un­der the weight of a biotech rout. Is it cheap yet?

Last fall, with the world grap­pling — not all that well — with a glob­al pan­dem­ic, any­thing might have seemed pos­si­ble for the new­ly mint­ed bil­lion­aires run­ning …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times